In this study, clear criteria were outlined for the evaluation of Ki-67, following the published guidelines by the then new IKWG [13], using the accepted “gold standard” Ki-67 monoclonal antibody MIB1, with evaluation of whole tumor sections, not limited to hot spots, and using a Ki-67 cutoff of 15% as defined by national and international recommendations at the time. The gene discussed is MKI67; the disease is neoplasm.